Bextra Was More Potent Than Celebrex. So Why Did It Vanish?
More potent in a recombinant enzyme assay does not mean better for patients. The safety record explains why that distinction matters.
THE HIVEPROSPECT WEEKLY
Good stories. Better questions.
Drug discoveries, difficult failures and the business decisions between them.
Filed under rights-diligence · Clear filter